Clinical utility of eslicarbazepine: current evidence

• Published in: Drug design, development and therapy Vol. 9; no. default; pp. 781 - 789
• Main Authors: Zaccara, Gaetano, Giovannelli, Fabio, Cincotta, Massimo, Carelli, Alessia, Verrotti, Alberto
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2015; Taylor & Francis Ltd; Dove Press; Dove Medical Press
• Subjects: Acetic acid; Affinity; Animals; Anticonvulsants - administration & dosage; Anticonvulsants - adverse effects; Anticonvulsants - therapeutic use; Antiepileptic agents; antiepileptic drugs; Carbamazepine; Children; Clinical trials; Convulsions & seizures; Deactivation; Dibenzazepines - administration & dosage; Dibenzazepines - adverse effects; Dibenzazepines - therapeutic use; Dosage and administration; Drug dosages; Drug metabolism; Drug resistance; Drug therapy; Epilepsy; Eslicarbazepine acetate; Esterases; Headache; Humans; Inactivation; Medical research; Mental disorders; Nausea; Neurological diseases; Oral administration; Oxcarbazepine; Patients; Pharmacology; pharmacoresistant epilepsy; Physiological aspects; Physiology; Plasma proteins; Review; Seizures; Seizures - diagnosis; Seizures - drug therapy; Sodium; Sodium channels (voltage-gated); Trade names; Vertigo; Vomiting; United States > US; Italy; epilepsy; antiepileptic drugs; eslicarbazepine acetate; oxcarbazepine; pharmacoresistant epilepsy; carbamazepine

Eslicarbazepine acetate (ESL) is a new antiepileptic drug whose mechanism of action is blockade of the voltage-gated sodium channel (VGSC). However, in respect to carbamazepine and oxcarbazepine, the active ESL metabolite (eslicarbazepine) affects slow inactivation of VGSC and has a similar affinity...